Total costs and quality-adjusted life years (QALYs) over the 2-year follow-up period
| Tapering csDMARD first | Tapering TNF-inhibitor first | |
| Total costs | €38 833 (€39 616) | €39 442 (€47 271) |
| Total healthcare costs* | €22 484 (€8069) | €13 616 (€9162) |
| Medication* | €19 858 (€7343) | €10 648 (€8642) |
| Medical consumption | €2297 (€1684) | €2393 (€1775) |
| Hospitalisation | €330 (€1319) | €575 (€2305) |
| Total productivity costs | €16 349 (€38 277) | €25 826 (€46 289) |
| Absenteeism | €17 581 (€39 576) | €23 577 (€45 382) |
| Presenteeism | €3290 (€9952) | €4777 (€14 620) |
| QALYs (EQ-5D, AUC), mean (SD) | 1.64 (0.22) | 1.65 (0.22) |
All values are indicated as mean (SD).
*p<0.0001 (linear regression adjusted for stratified randomisation).
AUC, area under the curve; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; EQ-5D, EuroQol questionnaire with 5 dimensions; ; TNF, tumour necrosis factor.